(All fields required)
Please enter a valid email.
Please enter your name.
What is : (So we know you are human.)
Please supply the correct answer.
The Leukemia and Lymphoma Center is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child’s unique needs. Learn more about our faculty and staff.
John P. Perentesis, MD, FAAP Director, Division of Oncology and Cancer Programs 513-636-8241 email@example.com
Director, Division of Oncology and Cancer Programs
Deb Kleisinger Endowed Chair of Novel Cancer Treatments
Co-Executive Director, Cancer and Blood Diseases Institute
Director, Leukemia / Lymphoma Program
Cincinnati Children's Principal Investigator, Children’s Oncology Group (COG)
Cincinnati Children's Principal Investigator, National Cancer Institute Pediatric Phase 1 Consortium
Professor, UC Department of Pediatrics
Acute myeloid leukemia; neuroblastoma; PNET / Ewing's sarcoma and osteosarcoma; new anticancer drug development; Phase I clinical trials
John P. Perentesis, MD, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs, and discovered genes important in the growth of normal and malignant cells. His laboratory is also developing the use of tumor and patients genetics research for personalizing therapies. In clinical research, he serves in leadership roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI Pediatric Phase I Consortium.
In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national Executive Committee for the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest, cooperative children's cancer research entity. He also is in leadership efforts in the COG for new therapies for leukemia, and adolescent and young adult cancers.
Dr. Perentesis has been elected by his peers for inclusion in Best Doctors in America® from 1998 to 2016.
MD: University of Michigan, Ann Arbor, MI, 1980.
Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.
Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.
Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.
Certification: Pediatrics, 1989; Hematology/Oncology, 1990.
Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.
Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.
Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.
Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.
Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.
Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.
Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.
Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.
Michael J. Absalon, MD, PhD Director, Medical Education Program 513-636-4266 firstname.lastname@example.org
Director, Medical Education Program
Associate Director, Leukemia/Lymphoma Program
Assistant Professor, UC Department of Pediatrics
Relapsed leukemia; lymphoma
BS: Lewis and Clark College, Portland, OR, 1987.
PhD: Massachusetts Institute of Technology, Cambridge, MA, 1994.
MD: Oregon Health Sciences University, Portland, OR, 1998.
Fellowship: St. Jude Children's Research Hospital, Memphis, TN, 2005.
Absalon MJ, Smith FO. Treatment strategies for pediatric acute myeloid leukemia. Expert Opin Pharmacother. 2009 Jan;10(1):57-79. Absalon MJ, McCarville MB, Liu T, Santana VM, Daw NC, Navid F. Pulmonary nodules discovered during the initial evaluation of pediatric patients with bone and soft-tissue sarcoma. Pediatr Blood Cancer. 2008 Jun;50(6):1147-53.
Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005 Oct 7;123(1):49-63.
Absalon MJ, Harding CO, Fain DR, Li L, Mack KJ. Leigh syndrome in an infant due to mitochondrial DNA depletion. Pediatr Neurology. 2001; 24:60-63.
Karen C. Burns, MD, MS Clinical Director, Cancer Survivorship Center 513-636-4266 email@example.com
Clinical Director, Cancer Survivorship Center
BA: University of Pennsylvania, Philadelphia, PA, 1995.
MD: Temple University, Philadelphia, PA, 1999.
Residency: Pediatrics, St. Christopher's Hospital for Children in Philadelphia, PA, 2002.
MS: Medical College of Wisconsin, 2005.
Fellowship: Medical College of Wisconsin, 2005.
Burns K, Broudreau C, Panepinto J. Attitudes Regarding Fertility in Adolescent Females Diagnosed with Cancer. J Pediatr Hematol Oncol. 2006 Jun;28(6): 350-354.
Burns K and Camitta B. Pyrite or True Gold? Journal of Pediatric Hematology/Oncology. 2005 May;27(5): 244.
Adrienne M. Hammill, MD, PhD Director, Hereditary Hemorrhagic Telangiectasia (HHT) Center 513-636-0673 firstname.lastname@example.org
Director, Hereditary Hemorrhagic Telangiectasia (HHT) Center
Director, Sturge-Weber Center of Excellence
Hemangiomas and vascular malformations; genetic predispositions to cancer
Dr. Adrienne M. Hammill is trained in pediatrics and hematology/oncology and is particularly interested in bringing new and/or better medical therapy options to the treatment of vascular anomalies. She is one of the medical physicians for the Hemangioma and Vascular Malformations team. She obtained her schooling at the University of Texas Southwestern and completed her residency and fellowship here at Cincinnati Children’s Hospital Medical Center. She is a dedicated professional and strives to improve the treatment for her patients. Cincinnati Children’s has been named a site for the brain vascular malformations consortium, which is a clinical research group funded by National Institutes of Health and the rare disease network and more recently a SWF Center of Excellence. She has developed a broader interest in Brain Vascular Malformations, and now heads our HHT Center and participates in the Cerebrovascular Clinic housed in Neurosurgery as well.
MD: University of Texas Southwestern Medical School, Dallas, TX, 2004.
PhD: University of Texas Southwestern Graduate School of Biomedical Sciences, Dallas, TX, 2004.
Residency: Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.
Fellowship: Cincinnati Children’s Hospital Medical Center.
Certifications: Pediatrics, 2008; Pediatric Hematology Oncology, 2011.
Hammill AM, Wentzel MS, Gupta A, Nelson S, Lucky A, Elluru R, Dasgupta R, Azizkhan RG, Adams DM. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011 Dec 1; 57(6):1018-1024.
Drolet BA, Trenor CC, Brandao L, Chiu YE, Chun RH, Dasgupta R, Garzon MC, Hammill AM, Johnson CM, Tlougan B, Blei F, David M, Elluru R, Frieden IJ, Friedlander SF, Iacobas I, Jensen JN, King DM, Lee MT, Nelson S, Patel M, Pope E, Powell J, Seefeldt M, Siegel DH, Kelly M, Adams DM. Consensus –derived practice standards plan for complicated Kaposiform hemangioendothelioma. J Pediatr. 2013 Jul; 163(1):285-91.
Jeng MR, Fuh B, Blatt J, Gupta A, Merrow AC, Hammill A, Adams D. Malignant transformation of infantile hemangioma to angiosarcoma: Response to chemotherapy with bevacizumab. Pediatr Blood Cancer. 2014 Nov; 61(11): 2115-7.
Adams D, Hammill A. Other vascular tumors. Sem Ped Surg. 2014 Aug; 23(4) 173-7.
Burkes SA, Adams DM, Hammill AM, Chute C, Eaton KP, Welge JA, Wickett RR, Visscher MO. Skin Imaging Modalities Quantify Progression and Stage of Infantile Hemangiomas. Br J Dermatol. 2015 Sep; 173(3):838-41.
Adams DM, Hammill AM, Mobberley-Schuman PS, Trenor CC. Comment on: Steroid-resistant kaposiform hemangioendothelioma: A retrospective study of 37 patients treated with vincristine and long-term follow-up. Pediatr Blood Cancer. 2015 Nov; 62(11):2056.
Maureen M. O'Brien, MD, MS Associate Director, Leukemia / Lymphoma Program 513-803-1678 email@example.com
Associate Director, Leukemia / Lymphoma Program
Associate Professor, UC Department of Pediatrics
MD: Harvard Medical School, Boston, MA, 2000.
Residency: Boston Combined Residency Program, Boston Children's Hospital and Boston Medical Center, Boston, MA, 2003.
Fellowship: Stanford University School of Medicine, Stanford, CA, 2007.
MS: Stanford University, Stanford, CA, 2008.
Certification: Pediatrics, 2003; Pediatric Hematology/Oncology, 2009.
Spicakova T, O'Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther. 2010 Nov;9(11):2970-81.
O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 May;54(5):694-702.
O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol. 2010 Mar 1;28(7):1232-9.
Jeng MR, O’Brien M, Wong W, Zoland J, Lea J, Tang N, Glader B. Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia. Haemophilia. 2009 Nov 15(6):1272-80.
Donaldson SS, O'Brien MM. Understanding the risk of second malignant tumors in children with Hodgkin's disease. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):4-5.
O’Brien MM, Lee-Kim Y, George T, McClain K, Twist C, Jeng M. Precursor B-cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis: case series and review of the literature. Pediatr Blood Cancer. 2008 Feb 50(2):381-3
O’Brien MM, Taub JW, Chang MN, Massey GV, Stine KC, Raimondi SC, Becton D, Ravindranath Y, Dahl GV. Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children’s Oncology Group Study POG 9421. J Clin Oncol. 2008 Jan 26(3):414-420.
Christine L. Phillips, MD 513-803-1126 firstname.lastname@example.org
Leukemia and lymphoma; leukemia pharmacogenetics; translational and clinical development of new drugs for high-risk and relapsed leukemias
Christine Phillips, MD, is an oncologist with a clinical focus on leukemia and lymphoma and a clinical and translational research focus on the development of novel therapies for pediatric leukemia and in leukemia pharmacogenetics.
Dr. Phillips earned her undergraduate degree in biochemistry and her medical degree from Indiana University, completed her residency in pediatrics at Children’s Memorial Hospital in Chicago, and her fellowship in pediatric hematology/oncology at Cincinnati Children’s, where she was co-chief fellow. She was a 2008 Hyundai Hope on Wheels Foundation Scholar.
MD: Indiana University School of Medicine, Indianapolis, IN, 2002.
Residency: Pediatrics, Children’s Memorial Hospital, Chicago, IL, 2005.
Fellowship: Pediatric Hematology/Oncology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 2010.
Certification: Pediatrics, 2005; Pediatric Hematology/Oncology, 2011.
Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with Melanotic Differentiation: Case Report and Review of the Literature. J Neurooncol. 2011 Jul;103(3):759-64.
Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley ITW, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 Polymorphism Increases Susceptibility to Childhood Acute Myeloid Leukemia. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Jacob (Jack) J.H. Bleesing, MD, PhD Associate Director, Immunodeficiency and Histiocytosis Program 513-636-4266 HLH@cchmc.org
Associate Director, Immunodeficiency and Histiocytosis Program
Co-Director, Diagnostic Immunology Laboratory
Immunobiology; translational research; immunologic methods development
MD: University of Leiden, Leiden, The Netherlands, 1989.
PhD: University of Leiden, Leiden, The Netherlands, 2002.
Residency: Pediatrics, University of Florida, Gainesville, Florida, 1993.
Fellowship: Allergy/Immunology, Duke University Medical Center, Durham, North Carolina, 1995.
Fellowship: Clinical Laboratory Immunology, National Institutes of Health, Bethesda, Maryland, 2001.
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5.
Eckrich MJ, Yang E, Domm J, Ho R, Calder C, Manes B, Bleesing J, Frangoul H. A Unique Clinical Presentation of X-Linked Lymphoproliferative Syndrome With a Novel Mutation in SH2D1A and Review of the Literature. J Pediatr Hematol Oncol. 2010 Oct 21.
Marsh RA, Bleesing JJ, Filipovich AH. Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency. J Immunol Methods. 2010 Oct 31;362(1-2):1-9.
Marsh RA, Villanueva J, Kim MO, Zhang K, Marmer D, Risma KA, Jordan MB, Bleesing JJ, Filipovich AH. Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations. Clin Immunol. 2009 Jul;132(1):116-23.
Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44.
Hansen MD, Filipovich AH, Davies SM, Mehta P, Bleesing J, Jodele S, Hayashi R, Barnes Y, Shenoy S. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008 Feb;41(4):349-53.
Bhatla D, Davies SM, Shenoy S, Harris RE, Crockett M, Shoultz L, Smolarek T, Bleesing J, Hansen M, Jodele S, Jordan M, Filipovich AH, Mehta PA. Reduced-intensity conditioning is effective and safe for transplantation of patients with Shwachman-Diamond syndrome. Bone Marrow Transplant. 2008 Aug;42(3):159-65.
Zhang K, Johnson JA, Biroschak J, Villanueva J, Lee SM, Bleesing JJ, Risma KA, Wenstrup RJ, Filipovich AH. Familial haemophagocytic lymphohistiocytosis in patients who are heterozygous for the A91V perforin variation is often associated with other genetic defects. Int J Immunogenet. 2007 Aug;34(4):231-3.
JJH Bleesing. Assays for B Cell and Germinal Center Development (unit 7.34). In Current Protocols in Immunology. JE Coligan, BE Bierer, DH Margulies, EM Shevach, W Strober (eds.). Hoboken: John Wiley & Sons, 2004.
JJH Bleesing, TA Fleisher, JM Puck. Autoimmune lymphoproliferative syndrome (ALPS). In Immunologic Disorders in Infants and Children. 5th ed. ER Stiehm, HD Ochs, JA Winkelstein (eds). Philadelphia, PA: WB Saunders, 2004.
Stella M. Davies, MBBS, PhD, MRCP Director, Bone Marrow Transplantation and Immune Deficiency 513-636-1371 email@example.com
Director, Bone Marrow Transplantation and Immune Deficiency
Jacob G. Schmidlapp Endowed Chair
MBBS: University of Newcastle-Upon-Tyne, England, 1981.
Clinical and Fellowship Training: The Royal Victoria Infirmary, Newcastle General Hospital and Great Ormond St. Hospital, 1981 to 1985.
PhD: University of Newcastle-Upon-Tyne, England, 1989.
Pediatric Fellowship: University of Minnesota, Minneapolis, MN, 1989 to 1993.
Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome -- acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010 Dec;203(2):180-6.
Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.
Mehta PA, Vinks AA, Filipovich A, Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2010 Oct;16(10):1458-62.
Sakagami T, Beck D, Uchida K, Suzuki T, Carey BC, Nakata K, Keller G, Wood RE, Wert SE, Ikegami M, Whitsett JA, Luisetti M, Davies S, Krischer JP, Brody A, Ryckman F, Trapnell BC. Patient-derived granulocyte / macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates. Am J Respir Crit Care Med. 2010 Jul 1;182(1):49-61.
Wang D, Zhang W, Kalfa TA, Grabowski G, Davies S, Malik P, Pan D. Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):19958-63.
Davies SM, Wang D, Wang T, Arora M, Ringden O, Anasetti C, Pavletic S, Casper J, Macmillan ML, Sanders J, Wall D, Kernan NA. Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants. Biol Blood Marrow Transplant. 2009 Mar;15(3):360-6.
Myers KC, Davies SM. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009 Mar;15(3):279-92. Review.
Sonata Jodele, MD Clinical Director, Division of Bone Marrow Transplantation & Immune Deficiency 513-636-1565 firstname.lastname@example.org
Clinical Director, Division of Bone Marrow Transplantation & Immune Deficiency
Bone marrow transplantation
MD: Vilnius University School of Medicine, 1988-1994.
Residency: Pediatrics, Downstate HSC at Brooklyn, Brooklyn, NY, 1998-2001.
Fellowship: Pediatric Hematology Oncology, Children's Hospital Los Angeles and Saban Research Institute, Keck School of Medicine University of Southern California, Los Angeles, CA, 2001-2004.
Certifications: Pediatrics, 2001; Pediatric Hematology / Oncology, 2004.
Licenses: California, 2001-present; Ohio, 2004-present.
Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, Lane A, Meller J, Medvedovic M, Chen J, Davies SM. The genetic fingerprint of susceptibility for transplant associated thrombotic microangiopathy. Blood. 2015 Nov 24.
Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Feb;22(2):307-15.
Jodele S, Laskin BL, Dandoy CE, Myers KC, El-Bietar J, Davies SM, Goebel J, Dixon BP. A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury. Blood Rev. 2015 May;29(3):191-204.
Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, Myers K, Grimley M, Bleesing J, El-Bietar J, Wallace G, Chima RS, Paff Z, Laskin BL. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a prospective study in children and young adults. Blood. 2014 Jul 24;124(4):645-53.
Jodele S, S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy. Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25.
Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, Davies SM, Pluthero FG, Lu L, Laskin BL. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013 Sep 19;122(12):2003-7.
Chima R, Rodney DC, Mi-Ok K, Li D, Wheeler DS, Davies SM, Jodele S. Improved Outcomes for Stem Cell Transplant Recipients Requiring Pediatric Intensive Care. Pediatric Critical Care Medicine. 2012.
Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplant associated-thrombotic microangiopathy. Blood. 2011 May 19.
Smith AR, Majhail NS, Macmillan ML, Defor TE, Jodele S, Lehmann LE, Krance R, Davies SM. Hematopoietic cell transplantation comorbidity index predicts transplant outcomes in pediatric patients. Blood. 2011 Jan 12.
Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.
Michael B. Jordan, MD Faculty, Langerhans Cell Histiocytosis Center 513-636-7287 email@example.com
Faculty, Langerhans Cell Histiocytosis Center
Histiocytic disorders: HLH and LCH
MD: UT Southwestern, Dallas, TX, 1993.
Residency: Children's Hospital of Dallas, Dallas, TX, 1996.
Fellowship: The Children's Hospital, Denver, CO, 2002.
Certification: American Board of Pediatrics, 1996; Sub-board of Pediatric Heme/Onc, 2002.
Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010 Dec 23;116(26):5824-31.
Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB, Bleesing JJ, Zhang K, Filipovich AH. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010 Aug 19;116(7):1079-82.
Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB, Bleesing JJ, Filipovich AH, Zhang K. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010 Jul 15;55(1):134-40.
Lykens JE, Terrell CE, Zoller EE, Divanovic S, Trompette A, Karp CL, Aliberti J, Flick MJ, Jordan MB. Mice with a selective impairment of IFN-gamma signaling in macrophage lineage cells demonstrate the critical role of IFN-gamma-activated macrophages for the control of protozoan parasitic infections in vivo. J Immunol. 2010 Jan 15;184(2):877-85.
Lin AA, Tripathi PK, Sholl A, Jordan MB, Hildeman DA. Gamma interferon signaling in macrophage lineage cells regulates central nervous system inflammation and chemokine production. J Virol. 2009 Sep;83(17):8604-15.
Marsh RA, Villanueva J, Zhang K, Snow AL, Su HC, Madden L, Mody R, Kitchen B, Marmer D, Jordan MB, Risma KA, Filipovich AH, Bleesing JJ. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009 Sep;76(5):334-44.
Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant. 2008 Oct;42(7):433-7.
Wojciechowski S, Jordan MB, Zhu Y, White J, Zajac AJ, Hildeman DA. Bim mediates apoptosis of CD127(lo) effector T cells and limits T cell memory. Eur J Immunol. 2006 Jul;36(7):1694-706.
Parinda A. Mehta, MD 513-636-4913 firstname.lastname@example.org
BA: Graduated from Parle College, Mumbai, India, 1988.
MD: G.S. Medical College and K.E.M Hospital, Mumbai, India, 1993.
Residency: Upstate Medical University (UMU) - State University of New York (SUNY), Syracuse, NY, 2002.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2005.
Certification: Board Certification, Pediatrics, 2002; Board Certification, Pediatric Hematology Oncology, License, State of Ohio.
Davies SM, Mehta PA. Pediatric acute lymphoblastic leukemia: is there still a role for transplant? Hematology Am Soc Hematol Educ Program. 2010;2010:363-7.
Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, Mo J, Myers K, Smolarek TA. Numerical chromosomal changes and risk of development of myelodysplastic syndrome--acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010 Dec;203(2):180-6.
Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5. doi: 10.1111/j.1399-3046.2010.01408.x
Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.
Mehta P, Locatelli F, Stary J, Smith FO. Bone marrow transplantation for inherited bone marrow failure syndromes. Pediatr Clin North Am. 2010 Feb;57(1):147-70. Review.
Michael J. Gelfand, MD Chief, Section of Nuclear Medicine, Department of Radiology and Medical Imaging 513-636-7650 email@example.com
Chief, Section of Nuclear Medicine, Department of Radiology and Medical Imaging
Professor, UC Department of Radiology
UC Department of Pediatrics
Michael J. Gelfand, MD, is chief of the Section of Nuclear Medicine at Cincinnati Children's Hospital Medical Center.
He received his BA from the University of Michigan and his MD from Stanford University. After two years at the National Institutes of Health, he completed residencies in pediatrics at Cincinnati Children's and nuclear medicine at the University of Cincinnati Medical Center.
Dr. Gelfand's research interests include I-123-MIBG imaging of neuroblastoma, new applications of hybrid imaging (PET/CT, SPECT/CT, PET/MRI) in pediatrics, and radiation dose reduction in nuclear medicine and hybrid imaging.
Dr. Gelfand has served as president of the Society of Nuclear Medicine, and served on the board of directors of that organization for 10 years.
Dr. Gelfand co-edited the textbooks Effective Use of Computers in Nuclear Medicine and Pediatric Nuclear Imaging. His publications include 126 journal articles and 31 book chapters. He has been an invited lecturer or visiting professor in France, Germany, the Netherlands, Italy, Argentina, Brazil, Japan and Australia.
BA: University of Michigan, Ann Arbor, MI, 1966.
MD: Stanford University, Stanford, CA, 1971.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1973-1975, 1977; Nuclear Medicine, University of Cincinnati, Cincinnati, OH, 1975-1977.
Certification: Pediatrics, 1978; Nuclear Medicine, 1978.
Gelfand MJ, Parisi MT, Treves ST. Pediatric Radiopharmaceutical Administered Doses: 2010 North American Consensus Guidelines. J Nucl Med. 2011 Jan 13.
Seo JH, Holland K, Rose D, Rozhkov L, Fujiwara H, Byars A, Arthur T, Degrauw T, Leach JL, Gelfand MJ, Miles L, Mangano FT, Horn P, Lee KH. Multimodality imaging in the surgical treatment of children with nonlesional epilepsy. Neurology. 2011 Jan 4;76(1):41-8.
Wagner LM, Gelfand MJ, Laor T, Ryckman FC, Al-Ghawi H, Bove KE. A Welcome Surprise: Nodular Fasciitis Presenting as Soft Tissue Sarcoma. J Pediatr Hematol Oncol. 2010 Oct 21.
Gelfand MJ. Dose reduction in pediatric hybrid and planar imaging. Q J Nucl Med Mol Imaging. 2010 Aug;54(4):379-88.
Sharp SE, Shulkin BL, Gelfand MJ, Salisbury S, Furman WL. 123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma. J Nucl Med. 2009 Aug;50(8):1237-43.
Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926-33.
Gelfand MJ. Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients. Pediatr Radiol. 2009 Feb;39 Suppl 1:S46-56
Gelfand MJ, Gruppo RA, Nasser MP. Ventilation-perfusion scintigraphy in children and adolescents is associated with a low rate of indeterminate studies. Clin Nucl Med. 2008 Sep;33(9):606-9.
Gelfand MJ, Lemen LC. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager. Semin Nucl Med. 2007 Sep;37(5):391-8. Review.
Wu SW, Graham B, Gelfand MJ, Gruppo RE, Dinopolous A, Gilbert DL. Clinical and positron emission tomography findings of chorea associated with primary antiphospholipid antibody syndrome. Mov Disord. 2007 Sep 15;22(12):1813-5.
Mary Sutton, MD Pediatric Neuro-oncologist, Division of Neurology 513-636-4222
Pediatric Neuro-oncologist, Division of Neurology
MD: University of Rochester School of Medicine and Dentistry, Rochester, NY, 1989.
Residency: Pediatrics, Children's Hospital, Boston, MA.
Fellowship: Neurology, Children's Hospital, Boston, MA.
Certification: Pediatrics, 1996; Neurology, 1996.
David W. Pruitt, MD Medical Director, Inpatient Pediatric Rehabilitation Unit 513-636-7480 firstname.lastname@example.org
Medical Director, Inpatient Pediatric Rehabilitation Unit
Director, Pediatric Rehabilitation Medicine Fellowship
UC Department of Neurology and Rehabilitation Medicine
Inpatient pediatric rehabilitation; pediatric cancer rehabilitation; pediatric neuro-oncology
BS: University of Notre Dame, Notre Dame, IN, 1994.
MD: Loyola University Stritch School of Medicine, Chicago, IL, 1998.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center; Physical Medicine and Rehabilitation, University of Cincinnati, Cincinnati, OH.
Certification: Physical Medicine and Rehabilitation, recertification 2014; Pediatric Rehabilitation Medicine, recertification 2014.
Visscher M, King A, Nie AM, Schaffer P, Taylor T, Pruitt D et al. A quality improvement collaborative project to reduce pressure ulcers in PICUs. Pediatrics. 2013: 131(6): e1950-60.
Pruitt DW, Ayyangar R, Craig K, White A, Neufeld JA. Pediatric brain tumor rehabilitation. J Pediatr Rehabil Med. 2011; 4(1): 59-70.
Pruitt DW, Tsai T. Common Comorbidities Associated With Cerebral Palsy. In: LJ Michaud (ed.): Physical Medicine and Rehabilitation Clinics of North America, 2009; 20(3):453-67.
Susan R. Rose, MD Member, Division of Endocrinology 513-636-4744 email@example.com
Member, Division of Endocrinology
Neuro-endocrinology; hypothalamic-pituitary injury; growth disorders; puberty disorders; thyroid disorders; late effects of cancer
Susan Rose is professor for the Division of Endocrinology at Cincinnati Children’s Hospital Medical Center within the University of Cincinnati. She has published over 100 review articles or chapters, and about 100 peer-reviewed articles. These include updating guidelines for care of congenital hypothyroidism and writing the chapter on thyroid for Fanaroff's and Avery's textbooks of neonatology. She’s served on the state newborn screening (NBS) committee in Tennessee. She is involved in long term follow up of newborn screening for CAH and congenital hypothyroidism with Region 4 and with the Federal Workgroup on NBS Standards.
She has clinical expertise and research interests in hypothalamic pituitary function, thyroid hormone disorders, and in disorders of growth or puberty. She has a special interest in the effects of central nervous system injury on hypothalamic-pituitary function. In addition, she has expertise and experience in evaluating the endocrine conditions associated with congenital bone marrow failure syndromes such as Fanconi anemia, Blackfan Diamond anemia, and Shwachman-Diamond syndrome. In addition, she is evaluating the endocrine consequences of hypothalamic-pituitary injury, including traumatic brain injury and injury from treatments for cancer, as well as comparing the relative efficacy of several treatments for precocious puberty. In this study, she will be developing growth curves specific to Fanconi anemia, recognizing that healthy children with FA may not grow along the typical growth pattern of other healthy children.
MD: Case Western Reserve School of Medicine, 1980.
MEd: School Psychology, University of Dayton, 1972.
Residency: The Cleveland Clinic, 1983.
Fellowship: National Institutes of Health, 1986.
Certification: Pediatrics, 1985; Pediatric Endocrinology, 1986.
Auble BA, Makoroff K, Bollepalli S, Weis T, Colliers T, Khoury J, Rose SR. Hypopituitarism in pediatric survivors of inflicted traumatic brain injury. J Neurotrauma. 2014 Feb 15;31(4):321-6.
Myers KC, Rose SR, Rutter MM, Mehta PA, Cole T, Harris RE. Endocrine evaluation of children with and without Shwachman-Bodian-Diamond syndrome gene mutations and Shwachman-Diamond syndrome. J Pediatr. 2013 Jun;162(6):1235-40.
Rutter MM, Collins J, Rose SR, Woo JG, Sucharew H, Sawnani H, Hor KN, Cripe LH, Wong BL. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord. 2012 Dec;22(12):1046-56.
Rose SR, Myers K, Rutter MM, Mueller R, Khuory JC, Mehta PA, Harris RE, Davies SM. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer. 2012 Oct;59(4):690-6.
Merchant TE, Rose SR, Bosley C, Wu S, Xiong X, Lustig RH. Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors. J Clin Oncol. 2011 Dec 20;29(36):4776-80.
Kaulfers AM, Backeljauw PF, Reifschneider K, Blum S, Michaud L, Weiss M, Rose SR. Endocrine dysfunction following traumatic brain injury in children. J Pediatr. 2010 Dec;157(6): 894-9.
Rose SR. Improved diagnosis of mild hypothyroidism using time-of-day normal ranges for thyrotropin. J Pediatr. 2010 Oct;157(4):662-7.
Slaughter JL, Meinzen-Derr J, Rose SR, Leslie ND, Chandrasekar R, Linard SM, Akinbi HT. The effects of gestational age and birth weight on false-positive newborn screening rates. Pediatrics. 2010 Nov;126(5):910-6.
Kazlauskaite R, Evans AT, Villabona CV, Abdu TAM, Ambrosi B, Atkinson AB, Choi CH, Courtney CH, Gonc EN, Maghnie M, Oelkers W, Rose SR, Soule SG, Tordjman K, Consortium for evaluation of corticotropin test in hypothalamic-pituitary insufficiency. Corticotropin tests for hypothalamic-pituitary adrenal insufficiency: A metaanalysis. J Clin Endocrinol Metab. 2008 Nov;93(11):4245-53.
Rose SR. Pharmacologic and physiologic regulators of the nocturnal TSH surge; A clinical research center study. Recent Advances and Research Updates. ISSN 0972-4699, 2007; 8:219-29.
Meilan M. Rutter, MD Member, Division of Endocrinology 513-636-4744 firstname.lastname@example.org
Bone health and calcium metabolism; disorders of growth, puberty and sex development; endocrine function in cancer survivors; endocrine function in neuromuscular disorders
Meilan Rutter is board-certified in pediatrics and pediatric endocrinology. She is an assistant professor of pediatrics in the Division of Endocrinology, and joined the faculty of Cincinnati Children's Hospital Medical Center within the UC College of Medicine in 2008. Currently, Dr. Rutter is assistant director of the Pediatric Endocrinology Fellowship Program.
Dr. Rutter received her degrees of Bachelor of Medicine and Bachelor of Surgery (MB, BCh) from the University of Wales College of Medicine. She completed her training in pediatrics in New Zealand, and was admitted to Fellowship of the Royal Australasian College of Physicians (FRACP) in 1995. She underwent fellowship training in pediatric endocrinology at Cincinnati Children's. She completed further pediatric residency training to achieve American Board of Pediatrics specialty and subspecialty board certification.
Dr. Rutter treats children and adolescents with endocrine disorders and diabetes mellitus. She serves as a consultant for the Neuromuscular Comprehensive Care Center and the Neuro-Oncology Program at Cincinnati Children's. Additionally, she is a member of the Disorders of Sex Development Center's interdisciplinary team.
MB, BCh: University of Wales College of Medicine, Cardiff, United Kingdom.
FRACP: Royal Australasian College of Physicians, New Zealand.
Residency: Auckland Children's Hospital and Dunedin Hospital, New Zealand; Cincinnati Children's, Cincinnati, OH.
Fellowship: Pediatric Endocrinology, Cincinnati Children's, Cincinnati, OH.
Certification: General Pediatrics, American Board of Pediatrics, 2002; Pediatric Endocrinology, American Board of Pediatrics, 2003; Pediatrics, Fellowship of the Royal Australasian College of Physicians, 1995.
Rose SR, Rutter MM, Mueller R, Harris M, Hamon B, Fletcher Bulluck A, Smith FO. Bone mineral density is normal in children with Fanconi anemia. Pediatr Blood Cancer. 2011 Dec 1;57(6):1034-8.
Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B. Endocrine aspects of Duchenne Muscular Dystrophy. Neuromuscul Disord. 2011 Apr;21(4):298-303.
Wong BL, Rutter MM, Rose SR, Clark E, Vonderhaar K. Growth hormone therapy in Duchenne Muscular Dystrophy. Best Evidence Statement, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio. 2009.
Rutter MM. What is an endocrinologist and why is endocrine care important for Duchenne? Action Duchenne newsletter. 2009.
Murray R, Rutter MM, Racine M, Rose SR. Report on The Endocrine Society’s 90th Annual Meeting. Highlights. 2008;16(4):1-36.
Rutter MM, Racine M, Rose SR. Report on The Endocrine Society’s 89th Annual Meeting. Highlights. 2007;15(3):2-30.
Rutter MM, Rose SR. Long-term endocrine sequelae of childhood cancer. Curr Opin Pediatr. 2007 Aug;19(4):480-7.
Rutter MM, Markoff E, Clayton L, Akeno N, Zhao G, Clemens TL, Chernausek SD. Osteoblast-specific expression of insulin-like growth factor-1 in bone of transgenic mice induces insulin-like growth factor binding protein-5. Bone. 2005 Feb;36(2):224-31.
Rutter MM, Prahalad S, Passo M, Backeljauw PF. Idiopathic hypercalcemia and eosinophilic fasciitis: a novel association. J Pediatr Endocrinol Metab. 2004 Sep;17(9):1251-4.
Rutter MM, Smith EP. Pseudohypoparathyroidism type Ia: late presentation with intact mental development. J Bone Miner Res. 1998 Jul;13(7):1208-9.
Richard L. McMasters, MD Staff Pathologist, Division of Pathology and Laboratory Medicine 513-636-4261 email@example.com
Staff Pathologist, Division of Pathology and Laboratory Medicine
Childhood leukemia, lymphoma and bone marrow failure syndrome; applications of flow cytometry in the diagnosis and management of these disorders.
MD: Baylor College of Medicine, Houston, TX, 1994.
Residency: Harbor-UCLA Medical Center, Torrance, CA, 2002.
Fellowships: Children's Hospital Los Angeles, Los Angeles, CA, 2003; LAC-USC Medical Center, Los Angeles, CA, 2004; Akron Children's Hospital, Akron, OH, 2005.
Certification: Anatomic and Clinical Pathology, 2003; Hematology (Pathology), 2004; Pediatric Pathology, 2005.
Kenneth R. Goldschneider, MD, FAAP Director, Pain Management Center 513-636-7768 firstname.lastname@example.org
Director, Pain Management Center
Professor, UC Department of Anesthesiology
Complex chronic pain conditions in infants, children and young adults, including those related to vascular malformations, epidermolysis bullosa and cancer.
MD: University of Connecticut Health Center School of Medicine, Farmington, CT, 1991.
Residency: Pediatrics, Duke University Medical Center, Durham, NC, 1991 - 1994; Anesthesiology, University of Pittsburgh Medical Center, Pittsburgh, PA, 1994-1997.
Fellowship: Pediatric Anesthesia, Children's Hospital of Pittsburgh, Pittsburgh, PA, 1997 - 1998; Pain Management, Longwood Combined Pain Fellowship, The Children's Hospital, Boston, MA, 1998-1999.
Certification: American Board of Pediatrics, 1994; American Board of Anesthesiology, 1998; ABA Pain Management, 2000.
Lynch-Jordan AM, Kashikar-Zuck S, Goldschneider KR. Parent perceptions of adolescent pain expression: the adolescent pain behavior questionnaire. Pain. 2010 Dec;151(3):834-42.
Goldschneider K, Lucky AW, Mellerio JE, Palisson F, del Carmen Viñuela Miranda M, Azizkhan RG. Perioperative care of patients with epidermolysis bullosa: proceedings of the 5th international symposium on epidermolysis bullosa, Santiago Chile, December 4-6, 2008. Paediatr Anaesth. 2010 Sep;20(9):797-804.
Goldschneider KR, Lucky AW. Pain management in epidermolysis bullosa. Dermatol Clin. 2010 Apr;28(2):273-82, ix. Review.
Meyer MJ, Goldschneider KR, Bielefeldt K, Zeltzer L, Lackner J, Keefer L. Functional abdominal pain in adolescence: a biopsychosocial phenomenon. J Pain. 2008 Nov;9(11):984-90.
Hosu L, Meyer MJ, Goldschneider KR. Cerebrospinal fluid cutaneous fistula after epidural analgesia in a child. Reg Anesth Pain Med. 2008 Jan-Feb;33(1):74-6.
Goldschneider KR, Racadio JM, Weidner NJ. Celiac plexus blockade in children using a three-dimensional fluoroscopic reconstruction technique: case reports. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):510-5.
Lynch AM, Kashikar-Zuck S, Goldschneider KR, Jones BA. Sex and age differences in coping styles among children with chronic pain. J Pain Symptom Manage. 2007 Feb;33(2):208-16.
Lynch AM, Kashikar-Zuck S, Goldschneider KR, Jones BA. Psychosocial risks for disability in children with chronic back pain. J Pain. 2006 Apr;7(4):244-51.
Kashikar-Zuck S, Vaught MH, Goldschneider KR, Graham TB, Miller JC. Depression, coping, and functional disability in juvenile primary fibromyalgia syndrome. J Pain. 2002 Oct;3(5):412-9.
Kashikar-Zuck S, Goldschneider KR, Powers SW, Vaught MH, Hershey AD. Depression and functional disability in chronic pediatric pain. Clin J Pain. 2001 Dec;17(4):341-9.
Mark Meyer, MD Medical Director, Pediatric Palliative and Comfort Care Team 513-636-4408 email@example.com
Medical Director, Pediatric Palliative and Comfort Care Team
Anesthesiologist, Department of Anesthesia
Associate Professor, UC Department of Anesthesiology
Palliative medicine; end of life care; anesthesiology; pain management
Mark Meyer, MD, is a board-certified anesthesiologist who completed his residency at the Cleveland Clinic in Cleveland, Ohio.
Dr. Meyer joined the Department of Anesthesia in 2003 following his Pediatric Anesthesia Fellowship at Cincinnati Children's Hospital Medical Center.
Dr. Meyer is a staff anesthesiologist, as well as an attending physician in the Division of Pain Management, caring for patients with acute pain. In addition, Dr. Meyer is an attending physician for StarShine Hospice, the pediatric hospice at Cincinnati Children's.
In 2006, Dr. Meyer received his board certification from the American Board of Hospice and Palliative Medicine. He has been an integral part of the development and implementation of the Pediatric Palliative and Comfort Care Team / PACT at Cincinnati Children's.
Dr. Meyer is the PACT consulting physician, partnering with families in order to offer a range of comprehensive, family-centered care for children with chronic, complex or life-threatening conditions.
MD: University of Cincinnati College of Medicine, Cincinnati, OH, 1998.
Residency: Cleveland Clinic Foundation, Cleveland, OH, 2002.
Fellowship: Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2003.
Certification: Anesthesiology, 2004; Hospice and Palliative Medicine, 2006.
Norbert J. Weidner, MD Anesthesiologist, Department of Anesthesia 513-636-4408 firstname.lastname@example.org
Pediatric palliative care; pediatric anesthesia
Norbert J. Weidner, MD, is a board-certified pediatrician as well as a board-certified anesthesiologist. Following training in pediatrics Cincinnati Children's Hospital Medical Center, as well as Dayton Children's Hospital, he pursued a fellowship in pediatric anesthesia/critical care/regional anesthesia in Melbourne, Australia, for one year.
Upon completion of his fellowship in 1988, Dr. Weidner joined the Department of Anesthesia at Cincinnati Children's. In addition to his staff duties as an anesthesiologist, Dr. Weidner was an attending staff in the pediatric intensive care unit for approximately two years.
To incorporate the fellowship training he received in Australia, Dr. Weidner began the pain management group at Cincinnati Children's. He has participated in the pain management group both in the care of acute postoperative pain as well as chronic pain management.
In 2004, Dr. Weidner received board certification with the American Board for Hospice and Palliative Medicine. Dr. Weidner has been affiliated with the hospice service at Cincinnati Children's since its inception and currently serves as StarShine Hospice's medical director.
Dr. Weidner is passionate about partnering with families to offer a range of comprehensive, family-centered care to children with chronic, complex or life-threatening conditions. His vision to address the needs of this patient population resulted in the development of the Pediatric Palliative and Comfort Care Team (PACT) here at Cincinnati Children's. Dr. Weidner serves as the director of this consulting service.
MD: Temple Medical School, Philadelphia, PA, 1975.
Residency: Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1975-77; Pediatrics, Dayton Children's Hospital, Dayton, OH 1981-82; Anesthesia, University of Cincinnati College of Medicine, Cincinnati, OH, 1985-87.
Fellowship: Pediatric Anesthesia, Royal Children's Hospital, Melbourne, Australia, 1988.
Certification: American Board of Anesthesiology, 1983; American Board of Pediatrics, 1989; Diplomat, American Board Medical Acupuncture, 2001; Hospice and Palliative Medicine, 2004.
Henderson C, Fitzgerald M, Weidner NJ, Hoehn S. Pediatrician Ambiguity in Understanding Palliative Sedation at the End of Life. Am J Hosp Palliat Care. 2015 Oct 5.
Benoit S, Antommaria AH, Weidner N, Lorts A. Difficult decision: What should we do when a VAD-supported child experiences a severe stroke? Pediatr Transplant. 2015 Mar;19(2):139-43.
Klick JC, Friebert S, Hutton N, Osenga K, Pituch KJ, Vesel T, Weidner NJ, Block SD, Morrison LJ, and on behalf of the American Board of Hospice and Palliative Medicine Competencies Work Group. Pediatrics: Developing Competencies for Pediatric Hospice and Palliative Medicine. Pediatrics. 2014 Dec;134(6):e1670-7.
Weidner NJ, Plantz D. Ethical Considerations in the Management of Analgesia in Terminally Ill Pediatric Patients. Journal of Pain and Symptom Management. 2014;(48)5:998-1003.
Weidner NJ, Cameron M, et al. End-of-Life Care for the Dying Child: What matters most to parents. Journal of Palliative Care. 2011;(27)4:279-286.
Goldschneider KR, Weidner NJ, Racadio JM. Celiac Plexus Blockade in Children Using a 3-D Fluoroscopic Reconstruction Technique. Reg Anes Pain Manage. 2007;32:510-15.
Weidner NJ. Pediatric palliative care. Curr Oncol Rep. 2007 Nov;9(6):437-9. Review.
Weidner NJ. The evolution of pediatric palliative medicine and its integration with anesthesia. Int Anesthesiol Clin. 2006 Winter;44(1):109-18. Review.
Weidner NJ. Developing an interdisciplinary palliative care plan for the patient with muscular dystrophy. Pediatr Ann. 2005 Jul;34(7):546-52. Review.
Paul R. Andreassen, PhD Member, Division of Experimental Hematology & Cancer Biology 513-636-0499 email@example.com
Member, Division of Experimental Hematology & Cancer Biology
Fanconi anemia; cell cycle check points; genetic instability; replication stress; relationship of DNA repair and chromatin; mitosis; cell biology
BS: Willamette University, Salem, Oregon, 1984.
PhD: University of Washington, Seattle, Washington, 1995.
Park JY, Singh TR, Nassar N, Zhang F, Freund M, Hanenberg H, Meetei AR, Andreassen PR. Breast
cancer-associated missense mutants of the PALB2 WD40 domain, which
directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair. Oncogene. 2014 Oct 2;33(40):4803-12.
Duan W, Gao L, Zhao W, Leon M, Sadee W, Webb A, Resnick K, Wu X, Ramaswamy B, Cohn DE, Shapiro C, Andreassen PR, Otterson GA, Villalona-Calero MA. Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents. Trans Res. 2013; 161(3): 156-64.
Du W, Rani R, Sipple J, Schick J, Myers KC, Mehta P, Andreassen PR, Davies SM, Pang Q. The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood. 2012;119(18): 4142-51.
Sin HS, Barski A, Zhang F, Kartashov AV, Nussenzweig A, Chen J, Andreassen PR, Namekawa SH. RNF8 regulates active epigenetic modifications and escape gene activation from inactive sex chromosomes in post-meiotic spermatids. Genes Dev. 2012 26(24):2737-48.
Zhang F, Bick G, Park JY, Andreassen PR. MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination. J Cell Sci. 2012; 125(24):6049-57.
Ichijima Y, Ichijima M, Lou Z, Nussenzweig A, Camerini-Otero RD, Chen J, Andreassen PR and Namekawa SH. MDC1 directs chromosome-wide silencing of the sex chromosomes in male germ cells. Genes Dev. 2011;25(9):959-71.
Kavanaugh GM, Wise-Draper TM, Morreale RJ, Morrison MA, Gole B, Schwemberger S, Tichy ED, Lu L, Babcock GF, Wells JM, Drissi R, Bissler JJ, Stambrook PJ, Andreassen PR, Wiesmuller L and Wells SI. The human DEK oncogene regulates DNA damage response signaling and repair. Nucleic Acids Res. 2011 ;39(17):7465-76.
Melendez J, Stengel K, Zhou X, Chauchan BK, Debidda M, Andreassen PR, Lang RA and Zheng Y. RhoA GTPase is dispensable for actomyosin regulation but is essential for mitosis in primary mouse embryonic fibroblasts. J Biol Chem. 2011;286(17):15132-7.
Montes de Oca R, Andreassen PR and Wilson KL. Barrier-to-autointegration factor influences specific histone modifications. Nucleus. 2011; 2(6):580-90.
Hayakawa T, Zhang F, Hayakawa N, Ohtani Y, Shinmyozu K, Nakayama J and Andreassen PR. MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks. J Cell Sci. 2010;127(Pt 7):1124-30.
Zhang F, Fan Q, Ren K, Auerbach AD and Andreassen PR. FANCJ/BRIP1 recruitment and regulation of FANCD2 in DNA damage responses. Chromosoma. 2010;119(6):637-49.
Pang Q and Andreassen PR. Fanconi anemia proteins and endogenous stresses. Mutat Res. 2009;668(1-2):42-53.
Fan Q, Zhang F, Barrett B, Ren K and Andreassen PR. A role for monoubiquitinated FANCD2 at telomeres in ALT cells. Nucleic Acids Res. 2009;37(6):1740-54.
Andreassen PR and Ren K. Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy. Curr. Cancer Drug Targets. 2009;9(1):101-17.
Zhang F, Fan Q, Ren K and Andreassen PR. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2. Mol Cancer Res. 2009;7(7):1110-8.
Mohammad Azam, PhD Member, Division of Experimental Hematology & Cancer Biology 513-803-1413 firstname.lastname@example.org
Azam M, Powers JT, Einhorn W, Huang WS, Shakespeare WC, Zhu X, Dalgarno D, Clackson T, Sawyer TK, Daley GQ. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des. 2010 Feb;75(2):223-7.
Zhang J, Adrián FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, Guo GR, Ding Q, Okram B, Choi Y, Wojciechowski A, Deng X, Liu G, Fendrich G, Strauss A, Vajpai N, Grzesiek S, Tuntland T, Liu Y, Bursulaya B, Azam M, Manley PW, Engen JR, Daley GQ, Warmuth M, Gray NS. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28;463(7280):501-6.
Nardi V, Azam M, Neverias O, Daley GQ. Immune-Mediated Protection Against BCR/ABL-Induced Leukemia: A Common Pathway Shared between IRF8/ICSBP and IFN alpha and beta. Blood. 2009.
Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ. Lin28 promotes transformation and is associated with advanced human malignancies. Nature Genetics. 2009 Jul;41(7):843-8.
Azam M, Seeliger M, Gray S, Kuriyan J, Daley GQ. Activation of tyrosine kinases by the mutation of gatekeeper residue. Nat Struct Mol Biol. 2008 Oct;15(10):1109-18.
Raz T, Nardi V, Azam M, Cortes J, Daley GQ. Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15;110(6):2102-9.
Azam M, Nardi V, Shakespeare WC, Metcalf CA 3rd, Bohacek RS, Wang Y, Sundaramoorthi R, Sliz P, Veach DR, Bornmann WG, Clarkson B, Dalgarno DC, Sawyer TK, Daley GQ. Activity of dual SRC-ABL inhibitors highlights role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9.
Azam M, and Daley GQ. Anticipating Clinical Resistance to Target-directed Agents: BCR-ABL an example. Molecular Diagnosis and Therapy. 2006;10(2):67-76.
Jose A. Cancelas Perez, MD, PhD Division Director of Research, Hoxworth Blood Center 513-558-1324 email@example.com
Division Director of Research, Hoxworth Blood Center
Deputy Director, Hoxworth Blood Center
Director, Research Flow Cytometry Core
Leader, Stem Cell Program
Medical Director of Cellular Therapies, Hoxworth Blood Center
Hematopoietic stem cell proliferation and differentiation
MD: Autonomous University of Madrid, Spain, 1989.
Residency: Hematology and Hematotherapy, University of Alcala de Henares, Madrid, Spain, 1993.
PhD: Faculty of Medicine, University of Alcala de Henares, Madrid, Spain, 1996.
Dumont LJ*, Cancelas JA*, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A. In vitro and in vivo quality of leukocyte-reduced apheresis platelets stored in a new platelet additive solution. Transfusion. 2012. (*both authors contributed equally).
Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner N. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol. 2013 Jan;125(1):159-68.
Dumont LJ, Cancelas J, Dumont DF, Siegel AH, Szczepiorkowski ZM, Rugg R, Pratt PG, Worsham DN, Hartman EL, Dunn SK, O’Leary M, Ransom JH, Michael RA, Macdonald VW. A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous platelets in healthy volunteers. Transfusion. 2013 Jan;53(1):128-37.
Taniguchi Ishikawa E, Cancelas JA. Lack of communication rusts and ages stem cells. Cell Cycle. 2012 Sep 1;11(17):3149-3150.
Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Liang HP, Fernández JA, Cancelas JA, Ryan MA, Kustikova O, Schambach A, Fu Q, Wang J, Fink LM, Petersen KU, Zhou D, Griffin JH, Baum C, Weiler H, Hauer-Jensen M. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med. 2012 Jul;18(7):1123-9.
Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Anrett JL, Santho RA, Agirre X, Perentesis JP, Deininger MW, Zheng Y, Bustelo XR, Williams DA, Cancelas JA. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation and survival. Blood. 2012 Jul 26;120(4):800-11.
Taniguchi Ishikawa E, Gonzalez-Nieto D, Ghiaur G, Dunn SK, Ficker AM, Murali B, Madhu M, Gutstein DE, Fishman GI, Barrio LC, Cancelas JA. Connexin-43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to bone marrow stromal cells. Proc Natl Acad Sci USA. 2012 Jun 5;109(23):9071-6.
Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood. 2012 Jun 21;119(25):6118-27.
Gonzalez-Nieto D, Li L, Köhler A, Ghiaur G, Ishikawa E, Sengupta A, Madhu M, Arnett J, Santho R, Dunn S, Fishman G, Gutstein D, Civitelli R, Barrio L, Gunzer M, Cancelas J. Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. Blood. 2012 May 31;119(22):5144-54.
Sengupta A, Ficker A, Dunn S, Madhu M, Cancelas JA. Bmi1 reprograms chronic myelogenous leukemia B-lymphoid progenitors to become B-ALL-initiating cells. Blood. 2012 Jan 12;119(2):494-502.
Hartmut Geiger, PhD Director, Mouse Core 513-636-1338 firstname.lastname@example.org
Director, Mouse Core
Hematopoietic stem cells; genetics; aging/longevity; plasticity of stem cells; mobilization; DNA-repair.
MS: Studies in chemistry at the University Karlsruhe, Germany and studies in biochemistry at the University Witten/Herdecke, Germany, 1996.
PhD: Max-Planck Institut für Immunbiologie in Freiburg, Germany. Plasticity of murine hematopoietic stem cells, 1999.
Postdoctoral Studies: University of Kentucky, Lexington, USA. Genetic analysis of hematopoiesis and aging/longevity in mice.
Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A, Köhler A, Liu W, Gunzer M, Jansen M, Ratner N, Le Cras TD, Waterstrat A, Van Zant G, Cancelas JA, Zheng Y, Geiger H. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization. Nat Med. 2010 Oct;16(10):1141-6.
Kalfa TA, Pushkaran S, Zhang X, Johnson JF, Pan D, Daria D, Geiger H, Cancelas JA, Williams DA, Zheng Y. Rac1 and Rac2 GTPases are necessary for early erythropoietic expansion in the bone marrow but not in the spleen. Haematologica. 2010 Jan;95(1):27-35.
Xu H, Eleswarapu S, Geiger H, Szczur K, Daria D, Zheng Y, Settleman J, Srour EF, Williams DA, Filippi MD. Loss of the Rho GTPase activating protein p190-B enhances hematopoietic stem cell engraftment potential. Blood. 2009 Oct 22;114(17):3557-66.
Geiger H, Rudolph KL. Aging in the lymphohematopoietic stem cell compartment. Trends Immunol. 2009 Jul;30(7):360-5. Review.
Geiger H, David S, Nattamai KJ, Jan V. Quantification of genomic mutations in murine hematopoietic cells. Methods Mol Biol. 2009;506:423-36.
Williams JP, Wu J, Johansson G, Rizvi TA, Miller SC, Geiger H, Malik P, Li W, Mukouyama YS, Cancelas JA, Ratner N. Nf1 mutation expands an EGFR-dependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell. 2008 Dec 4;3(6):658-69.
Milsom MD, Jerabek-Willemsen M, Harris CE, Schambach A, Broun E, Bailey J, Jansen M, Schleimer D, Nattamai K, Wilhelm J, Watson A, Geiger H, Margison GP, Moritz T, Baum C, Thomale J, Williams DA. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells. Cancer Res. 2008 Aug 1;68(15):6171-80.
Diwan A, Koesters AG, Capella D, Geiger H, Kalfa TA, Dorn GW 2nd. Targeting erythroblast-specific apoptosis in experimental anemia. Apoptosis. 2008 Aug;13(8):1022-30.
Daria D, Filippi MD, Knudsen ES, Faccio R, Li Z, Kalfa T, Geiger H. The retinoblastoma tumor suppressor is a critical intrinsic regulator for hematopoietic stem and progenitor cells under stress. Blood. 2008 Feb 15;111(4):1894-902.
H. Leighton (Lee) Grimes, PhD Director, Cancer Pathology Program, Division of Experimental Hematology & Division of Pathology 513-636-6089 email@example.com
Director, Cancer Pathology Program, Division of Experimental Hematology & Division of Pathology
Co-Leader, Program in Hematologic Malignancies of Cincinnati Children's Hospital Medical Center, Cancer and Blood Diseases Institute
Transcriptional control of hematopoiesis and cancer.
Visit the Grimes Lab.
Dr. Grimes has a broad background in hematopoiesis, molecular biology, and molecular oncology including modeling of hematopoiesis, myelopoiesis and leukemia. His work on the Growth factor independent-1 (Gfi1) transcriptional repressor protein has spanned the initial identification of Gfi1 in a model of leukemia and the role of Gfi1 in normal myeloid biology, to the identification of GFI1 mutations in patients with severe congenital neutropenia (SCN) and non-immune chronic idiopathic neutropenia of adults (NI-CINA). His work utilizes Gfi1 as a molecular probe to understand both normal myeloid development and innate immune action, as well as marrow failure and transformation.
PhD: Immunology and Molecular Pathology, University of Florida, Gainesville, FL.
Postdoctoral Fellow: Fox Chase Cancer Center.
Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, Wellendorf AM, Valencia CA, Paddison PJ, Horwitz MS, Grimes HL#, Lutzko C#, Cancelas JA#. Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. J Clin Invest. 2015 Aug 3;125(8):3103-16. # shared corresponding author.
Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest. 2014 Jan;124(1):222-36.
Phelan JD, Saba AI, Olsson A, Zeng H, Kosan C, Messer MS, Hildeman D, Aronow B, Möröy T, Grimes HL. Growth factor independent-1 maintains Notch1-dependent transcriptional programming of lymphoid precursors. PLoS Genetics. 2013;9(9):e1003713.
Khandanpour C*, Phelan JD*, Vassen L, Schutte J, Chen R, Horman SR, Gaudreau MC, Krongold J, Zhu J, Paul WE, Duhrsen U, Gottgens B, Grimes HL# Moroy T#. Growth factor independence 1 (Gfi1) antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia. Cancer Cell. 2013 Feb 11;23(2):200-14. * equal first author, # shared corresponding author.
Horman SR, Velu CS, Chaubey A, Bourdeau T, Zhu J, Paul WE, Gebelein B, Grimes HL. Gfi1 integrates progenitor versus granulocytic transcriptional programming. Blood. 2009 May 28;113(22):5466-75.
Velu CS, Baktula AM, Grimes HL. Gfi1 regulates miR-21 and miR-196b to control myelopoiesis. Blood. 2009 May 7;113(19):4720-8.
Horman SR, Velu CS, Chaubey A, Bourdeau T, Zhu J, Paul WE, Gebelein B, Grimes HL. Gfi1 integrates progenitor versus granulocytic transcriptional programming. Blood. 2009 May 28;113(22):5466-75.
Li-Kroeger D, Witt LM, Grimes HL, Cook TA, Gebelein B. Hox and senseless antagonism functions as a molecular switch to regulate EGF secretion in the Drosophila PNS. Dev Cell. 2008 Aug;15(2):298-308.
Zarebski1 A, Velu CS, Baktula AM, Bourdeau T, Horman SR, Basu S, Bertolone SJ, Horwitz M, Hildeman DA, Trent JO, Grimes HL. The Human Severe Congenital Neutropenia-Associated Gfi1N382S Mutant Blocks Murine Granulopoiesis Through CSF1. Immunity. 2008 Mar;28(3):370-80.
Person RE, Li FQ, Duan Z, Benson KF, Wechsler J, Papadaki HA, Eliopoulos G, Kaufman C, Bertolone SJ, Nakamoto B, Papayannopoulou T, Grimes HL, Horwitz M. Gfi1 Proto-Oncogene Mutation Causes Human Neutropenia and Targets Neutrophil Elastase. Nature Genetics. 2003 March 1;30: 295 - 300.
Gang Huang, PhD Member, Division of Experimental Hematology & Cancer Biology 513-636-3214 firstname.lastname@example.org
Research in Dr. Huang’s laboratory focuses on genetic and epigenetic regulations of blood cell normal development and leukemia. The lab first demonstrated that AML1/CBFβ (a hetero-dimer transcription factor) and mixed-lineage leukemia (MLL) protein (an enzyme which methylates lysine 4 of histone H3 tails), form a regulatory complex, which is important for normal blood development and acts as a tumor suppressor in leukemia. Mutations in either one of these three genes account for majority of acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS).
The lab also found that the AML1/CBFβ/MLL complex regulates another transcription factor, PU.1, through the upstream regulatory region of the PU.1 gene and that the epigenetic changes of the histone tails occurring in the PU.1 regulatory region correlate with the PU.1 expression level. PU.1 expression level changes are critical for blood cell differentiation and dysregulation of PU.1 dosages leading to leukemia.
This research will provide new insight into the interplay between genetics and epigenetics in normal blood development and leukemia. It will also help to develop generic drugs for most of the AML, ALL and MDS, which will benefit the future clinical treatments.
BS: Peking University, College of Science, Beijing, P.R. China, 1991.
MS: Inner Mongolia University, Graduate School of Science, Huhhort, P.R. China, 1994.
PhD: Kyoto University, Graduate School of Medicine, Kyoto, Japan, 2001.
Staber PB, Zhang P, Ye M, Welner R, Nombela-Arrieta C, Bach C, Kerenyi M, Bartholdy BA, Zhang H, Alberich-Jorda M, Lee S, Yang H, Ng F, Zhang J, Leddin M, Silberstein LE, Hoefler G, Orkin S, Gottgens B, Rosenbauer F, Huang G, Tenen DG. Sustained PU.1 Levels Balance Cell Cycle Regulators to Prevent Exhaustion of Adult Hematopoietic Stem Cells. Mol Cell. 2013.
Hirai H, Kamio N, Huang G, Matsusue A, Ogino S, Kimura N, Satake S, Ashihara E, Imanishi J, Tenen MD, DG, Maekawa T. Cyclic AMP Responsive Element Binding proteins are involved in “emergency” granulopoiesis through the upregulation of CCAAT/Enhancer Binder Protein. PlosONE. 2013
Zhang Y, Chen A, Yan XM, Huang G. Disordered epigenetic regulation in MLL-related leukemia. Int J Hematol. 2012 Oct;96(4):428-37.
Zhang Y, Yan XM, Sashida G, Zhao XH, Rao YL, Goyama S, Whitman SP, Zorko N, Bernot K, Conway R, Witte D, Wang QF, Tenen DG, Xiao ZJ, Marcucci G, Mulloy J, Grimes HL, Caligiuri MA, Huang G. Mll partial tandem duplication (Mll-PTD) causes abnormal hematopoiesis in mice by reprogramming, enhancing self-renewal, lineage skewing and blocking myeloid differentiation. Blood. 2012 Aug 2;120(5):1118-29.
Zorko N, Bernot KS, Whitman SP, Siebenaler RF, Ahmed E, Marcucci GG, Yanes DA, McConnell KK, Mao C. Kalu C, Zhang XL, Jarjoura D, Dorrance AM, Lee BH, Huang G, Marcucci G, Caligiuri MA. Mll Partial Tandem Duplication and Flt3-Internal Tandem Duplication in a Double Knock-in Mouse Recapitulates Features of Counterpart Human Acute Myeloid Leukemias. Blood. 2012 Aug 2;120(5):1130-6.
Huang G, Zhao XH, Wang L, Elf S, Xu H, Zhao XY, Sashida G, Zhang Y, Liu Y, Lee J, Menendez S, Yang YY, Yan XM, Zhang P, Tenen DG, Osato M, Hsieh JDJ, Nimer SD. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood. 2011;118(25):6544-52.
Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, Jiang Y, Cole PA, Zhang J, Melnick A, Roeder RG, Nimer SD. The leukemogenicity of AML1-ETO is dependent on site-specific lysine Acetylation. Science. 2011;333(6043):765-9.
Huang G, Zhang P, Hirai H, Elf S, Yan XM, Chen Z, Koschmieder S, Okuno Y, Dayaram T, Growney JD, Shivdasani RA, Gilliland DG, Speck NA, Nimer SD, Tenen DG. PU.1 is a major downstream target of AML1/RUNX1 in adult hematopoiesis. Nat Genet. 2008;40:51-60.
Ashish R. Kumar, MD, PhD Director, Langerhans Cell Histiocytosis Center 513-803-1631 email@example.com
Director, Langerhans Cell Histiocytosis Center
Director, Pediatric Hematology/Oncology Fellowship Program
Member, Division of Bone Marrow Transplantation & Immune Deficiency
Childhood cancer and blood disorders; immune deficiency
Dr. Kumar received his medical degree from L.T.M. Medical College, Mumbai, India, his PhD in anatomy and cell biology from the University of Iowa, pediatric residency training at the Mayo Clinic and fellowship in pediatric hematology / oncology / BMT at the University of Minnesota. He was appointed to the faculty of the University of Minnesota in the Department of Pediatrics where he was a member of the programs in pediatric leukemia and global pediatrics. He is currently an associate professor of pediatrics in the Division of Bone Marrow Transplantation and Immune Deficiency at Cincinnati Children's within the University of Cincinnati College of Medicine. Dr. Kumar’s laboratory is engaged in researching the biology of infant leukemia. Discoveries made in his laboratory have significantly enhanced the current understanding of leukemia. Dr. Kumar is also active in education. He has delivered invited lectures and grand round presentations on various topics.
Visit the HLH Center of Excellence.
Learn more about the 700 Miles to Hope Bike Ride.
MD: LTM Medical College, Mumbai, India.
Residency: Mayo Clinic, Rochester, MN.
Fellowship: University of Minnesota, Minneapolis, MN.
PhD: University of Iowa, Iowa City, IA.
Certification: General Pediatrics; Pediatric Hematology/Oncology Subspecialty.
Licenses: State of Ohio; State of Minnesota.
Aydin SE, Kilic SS, Aytekin C, Kumar A, Porras O, Kainulainen L, Kostyuchenko L, Genel F, Kütükcüler N, Karaca N, Gonzalez-Granado L, Abbott J, Al-Zahrani D, Rezaei N, Baz Z, Thiel J, Ehl S, Marodi L, Orange JS, Sawalle-Belohradsky J, Keles S, Holland SM, Sanal Ö, Ayvaz DC, Tezcan I, Al-Mousa H, Alsum Z, Hawwari A, Metin A, Matthes-Martin S, Hönig M, Schulz A, Picard C, Barlogis V, Gennery A, Ifversen M, van Montfrans J, Kuijpers T, Bredius R, Dückers G, Al-Herz W, Pai SY, Geha R, Notheis G, Schwarze CP, Tavil B, Azik F, Bienemann K, Grimbacher B, Heinz V, Gaspar HB, Aydin R, Hagl B, Gathmann B, Belohradsky BH, Ochs HD, Chatila T, Renner ED, Su H, Freeman AF, Engelhardt K, Albert MH; inborn errors working party of EBMT. DOCK8 Deficiency: Clinical and Immunological Phenotype and Treatment Options - a Review of 136 Patients. J Clin Immunol. 2015 Feb;35(2):189-98.
Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link KA, Dasgupta N, Aronow B, Huang G, Mulloy JC, Kumar AR. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia. Blood. 2015;125(16):2544-52.
Marsh RA, Rao MB, Gefen A, Bellman D, Mehta PA, Khandelwal P, Chandra S, Jodele S, Myers KC, Grimley M, Dandoy C, El-Bietar J, Kumar AR, Leemhuis T, Zhang K, Bleesing JJ, Jordan MB, Filipovich AH, Davies SM. Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen. Biol Blood Marrow Transplant. 2015 Aug;21(8):1460-70.
Cai X, Gao L, Teng L, Ge J, Oo ZM, Kumar AR, Gilliland DG, Mason PJ, Tan K, Speck NA. Runx1 Deficiency Decreases Ribosome Biogenesis and Confers Stress Resistance to Hematopoietic Stem and Progenitor Cells. Cell Stem Cell. 2015 Jul;pii:S1934-5909(15)00262-3.
Karkare S, Chhipa RR, Anderson J, Liu X, Henry H, Gasilina A, Nassar N, Roychoudhury J, Clark JP, Kumar A, Pauletti GM, Ghosh PK, Dasgupta B. Direct inhibition of retinoblastoma phosphorylation by nimbolide causes cell-cycle arrest and suppresses glioblastoma growth. Clin Cancer Res. 2014 Jan;20(1):199-212.
Khandelwal P, Lawrence J, Filipovich AH, Davies SM, Bleesing JJ, Jordan MB, Mehta P, Jodele S, Grimley MS, Kumar A, Myers K, Marsh RA. The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients. Pediatr Transplant. 2014 Feb;18(1):94.
Liu X, Chhipa RR, Pooya S, Wortman M, Yachyshin S, Chow LM, Kumar A, Zhou X, Sun Y, Quinn B, McPherson C, Warnick RE, Kendler A, Giri S, Poels J, Norga K, Viollet B, Grabowski GA, Dasgupta B. Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK. Proc Natl Acad Sci USA. 2014 Jan;111(4):E435-44.
Zhou J, Wu J, Li B, Liu D, Yu J, Yan X, Zheng S, Wang J, Zhang L, Zhang L, He F, Li Q, Chen A, Zhang Y, Zhao X, Guan Y, Zhao X, Yan J, Ni J, Nobrega MA, Löwenberg B, Delwel R, Valk PJ, Kumar A, Xie L, Tenen DG, Huang G, Wang QF. PU.1 is Essential for MLL Leukemia Partially via Crosstalk with the MEIS/HOX Pathway. Leukemia. 2014 Jul;28(7):1436-48.
Jing H, Zhang Q, Zhang Y, Hill BJ, Dove CG, Gelfand EW, Atkinson TP, Uzel G, Matthews HF, Mustillo PJ, Lewis DB, Kavadas FD, Hanson IC, Kumar AR, Geha RS, Douek DC, Holland SM, Freeman AF, Su HC. Somatic reversion in dedicator of cytokinesis 8 immunodeficiency modulates disease phenotype. The Journal of allergy and clinical immunology. 2014 Jun;133(6):1667-75.
Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper JT, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan BM, Bleesing J, Filipovich A. Allogeneic Hematopoietic Cell Transplantation for XIAP Deficiency: An International Survey Reveals Poor Outcomes. Blood. 2013 Feb 7;121(6):877-83.
Role of MEIS1 in hematopoiesis and hematopoietic transformation. Principal Investigator. National Institutes of Health/National Heart, Lung, and Blood Institute. Jul 2012-Jun 2017.
Novel therapeutics of targeting mTOR pathway in T-cell leukemia. Co-investigator. National Institutes of Health/National Cancer Institute. Jul 2015-Jun 2017.
Ruhikanta A. Meetei, PhD Member, Experimental Hematology and Cancer Biology 513-636-1768 firstname.lastname@example.org
Member, Experimental Hematology and Cancer Biology
Fanconi anemia; chromosome instability; DNA repair; multiprotein complex
BS: Manipur University, India, 1989.
MS: Manipur University, India, 1992.
PhD: Indian Institute of Science, Bangalore, India, 2000.
Singh TR, Saro D, Ali AM, Zheng XF, Du CH, Killen MW, Sachpatzidis A, Wahengbam K, Pierce AJ, Xiong Y, Sung P, Meetei AR. MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. Mol Cell. 2010 Mar 26;37(6):879-86.
Singh TR, Bakker ST, Agarwal S, Jansen M, Grassman E, Godthelp BC, Ali AM, Du CH, Rooimans MA, Fan Q, Wahengbam K, Steltenpool J, Andreassen PR, Williams DA, Joenje H, de Winter JP, Meetei AR. Impaired FANCD2 monoubiquitination and hypersensitivity to camptothecin uniquely characterize Fanconi anemia complementation group M. Blood. 2009 Jul 2;114(1):174-80.
Ali AM, Kirby M, Jansen M, Lach FP, Schulte J, Singh TR, Batish SD, Auerbach AD, Williams DA, Meetei AR. Identification and characterization of mutations in FANCL gene: a second case of Fanconi anemia belonging to FA-L complementation group. Hum Mutat. 2009 Jul;30(7):E761-70.
Ali AM, Singh TR, Meetei AR. FANCM-FAAP24 and FANCJ: FA proteins that metabolize DNA. Mutat Res. 2009 Jul 31;668(1-2):20-6. Review.
Singh TR, Ali AM, Busygina V, Raynard S, Fan Q, Du CH, Andreassen PR, Sung P, Meetei AR. BLAP18/RMI2, a novel OB-fold-containing protein, is an essential component of the Bloom helicase-double Holliday junction dissolvasome. Genes Dev. 2008 Oct 15;22(20):2856-68.
Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, Steltenpool J, Stone S, Dokal I, Mathew CG, Hoatlin M, Joenje H, de Winter JP, Wang W. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet. 2005 Sep;37(9):958-63.
James C. Mulloy, PhD Member, Experimental Hematology & Cancer Biology 513-636-1844 email@example.com
Member, Experimental Hematology & Cancer Biology
BA: St. Anselm College, Manchester, NH, 1986.
MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1989.
PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1992.
Goyama S, Schibler J, Gasilina A, Shrestha M, Lin S, Link KA, Chen J,
Whitman SP, Bloomfield CD, Nicolet D, Assi SA, Ptasinska A, Heidenreich
O, Bonifer C, Kitamura T, Nassar NN, Mulloy JC. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO. Leukemia. 2016;30(3):728-39.
Maiques-Diaz A, Hernando M, Sánchez-López A, Rio-Machin A, Shrestha M, Mulloy JC, Cigudosa JC, Alvarez S. MAPK8-mediated stabilization of SP1 is essential for RUNX1-RUNX1T1 - driven leukaemia. Br J Haematol. 2016 Mar;172(5):807-10.
Benito JM, Godfrey L, Kojima K, Hogdal L, Wunderlich M, Geng H, Marzo I, Harutyunyan KG, Golfman L, North P, Kerry J, Ballabio E, Chonghaile TN, Gonzalo O, Qiu Y, Jeremias I, Debose L, O'Brien E, Ma H, Zhou P, Jacamo R, Park E, Coombes KR, Zhang N, Thomas DA, O'Brien S, Kantarjian HM, Leverson JD, Kornblau SM, Andreeff M, Müschen M, Zweidler-McKay PA, Mulloy JC, Letai A, Milne TA, Konopleva M. MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199. Cell Rep. 2015 Dec 29;13(12):2715-27.
Thowfeik FS, AbdulSalam SF, Wunderlich M, Wyder M, Greis KD, Kadekaro AL, Mulloy JC, Merino EJ. A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway Compounds. Chembiochem. 2015 Nov;16(17):2513-21.
Glait-Santar C, Desmond R, Feng X, Bat T, Chen J, Heuston E, Mizukawa B, Mulloy JC, Bodine DM, Larochelle A, Dunbar CE. Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells. Stem Cells. 2015 Dec;33(12):3635-42.
Ågerstam H, Karlsson C, Hansen N, Sandén C, Askmyr M, von Palffy S, Högberg C, Rissler M, Wunderlich M, Juliusson G, Richter J, Sjöström K, Bhatia R, Mulloy JC, Järås M, Fioretos T. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci USA. 2015 Aug 25;112(34):10786-91.
Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant hematopoiesis. Blood. 2015 Apr;125(17):2630-2640.
Roychoudhury J, Clark JP, Gracia-Maldonado G, Unnisa Z, Wunderlich M, Link KA, Dasgupta N, Aronow B, Huang G, Mulloy JC, Kumar AR. MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia. Blood. 2015 Apr;125(16):2544-52.
Goyama S, Huang G, Kurokawa M, Mulloy JC. Posttranslational modifications of RUNX1 as potential anticancer targets. Oncogene. 2015 Jul;34(27):3483-92.
Vadukoot AK, AbdulSalam SF, Wunderlich M, Pullen ED, Landero-Figueroa J, Mulloy JC, Merino EJ. Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells. Bioorganic & Medicinal Chemistry. 2014 Dec;22(24):6885-92.
Conferring in vivo metabolic resistance to a highly selective anti-AML agent. Co-Investigator. National Institutes of Health/National Cancer Institute. May 2014-Apr 2017.
Rapid Suppression of Food Allergy with Anti-Fc Epsilon Rl Alpha Antibody. Co-Investigator. Food Allergy Research & Education Inc. Apr 2014-Mar 2017.
Suppression of IgE-Mediated Disease by Polyclonal Rapid Desensitization. Co-Investigator. National Institutes of Health/National Institute of Allergy and Infectious Diseases. Jul 2014-Jun 2019.
A new Hydrogen Peroxide-activated Agent that Selectively. Co-Principal Investigator. Center for Clinical and Translational Science and Training. Jul 2015-Jun 2016.
Yi Zheng, PhD Director, Experimental Hematology and Cancer Biology 513-636-0595 firstname.lastname@example.org
Director, Experimental Hematology and Cancer Biology
Katherine Stewart Waters Endowed Chair
Co-Director, Cancer and Blood Diseases Institute
Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.
Visit the Zheng Lab.
BS: Tsinghua University, Beijing, China, 1986.
MS: Cornell University, Ithaca, NY, 1988.
PhD: Cornell University, Ithaca, NY, 1991.
Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.
Kesarwani M, Huber E, Kincaid Z, Evelyn CR, Biesiada J, Rance M, Thapa MB, Shah NP, Meller J, Zheng Y, Azam M. Targeting substrate-site in Jak2 kinase prevents emergence of genetic resistance. Sci Report. 2015. In press.
Konstantinidis DG, Giger KM, Risinger M, Pushkaran S, Zhou P, Dexheimer P, Yerneni S, Andreassen P, Klingmüller U, Palis J, Zheng Y, Kalfa TA. Cytokinesis failure in RhoA-deficient mouse erythroblasts involves actomyosin and midbody dysregulation and triggers p53 activation. Blood. 2015 Jul 30. [Epub ahead of print]
Barry DM, Xu K, Meadows SM, Zheng Y, Norden PR, Davis GE, Cleaver O. Cdc42 is required for cytoskeletal support of endothelial cell adhesion during blood vessel formation. Development. 2015 Aug 7. [Epub ahead of print]
Yang JQ, Kalim KW, Li Y, Zhang S, Hinge A, Filippi MD, Zheng Y, Guo F. RhoA orchestrates glycolysis for TH2 cell differentiation and allergic airway inflammation. J Allergy Clin Immunol. 2015 Jun 19. [Epub ahead of print]
Lin Y, Zheng Y. Approaches for targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov. 2015 Sep;10(9):991-1010.
Zandvakili I, Davis AK, Hu G, Zheng Y. Loss of RhoA exacerbates, rather than dampens, oncogenic K-Ras induced lung adenoma formation in mice. PLoS One. 2015 Jun 1;10(6):e0127923.
Evelyn CR, Biesiada J, Duan X, Tang H, Shang X, Nelson S, Seibel WL, Meller J, Zheng Y. Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme. J Biol Chem. 2015 May 15;290(20):12879-98.
Mikelis CM, Simaan M, Ando K, Fukuhara S, Sakurai A, Amornphimoltham P, Masedunskas A, Weigert R, Chavakis T, Adams RH, Offermanns S, Mochizuki N, Zheng Y, Gutkind JS. RhoA and ROCK mediate histamine-induced vascular leakage and anaphylactic shock. Nat Commun. 2015 Apr 10;6:6725.
Li J, Zhang L, Chen Z, Xie M, Huang L, Xue J, Liu Y, Liu N, Guo F, Zheng Y, Kong J, Zhang L. Cocaine activates Rac1 to control structural and behavioral plasticity in caudate putamen. Neurobiol Dis. 2015 Mar;75:159-76.
Chang KH, Nayak RC, Roy S, Perumbeti A, Wellendorf AM, Bezold KY, Pirman M, Hill SE, Starnes J, Loberg A, Zhou X, Inagami T, Zheng Y, Malik P, Cancelas JA. Vasculopathy-associated hyperangiotensinemia mobilizes haematopoietic stem cells/progenitors through endothelial AT₂R and cytoskeletal dysregulation. Nat Commun. 2015 Jan 9;6:5914.
Cincinnati Center of Excellence in Molecular Hematology. Principal investigator. National Institutes of Health. Sep 2010–June 2016. NIH P30 DK090971 S2.
Lineage Determination and Tissue Homeostasis in the aged Hematopoietic System. Principal investigator. National Institutes of Health. Aug 2011–July 2016. NIH R01AG040118.
Rho GTPase inhibitors for refrigerated platelet storage. Co-principal investigator. National Institutes of Health. Aug 2014–July 2016. NIH R43HL123103.
Targeting Cdc42 for bone marrow transplant therapies. Principal investigator. National Institutes of Health. April 2015—April 2020. NIH R01CA193350.
Stem cell aging and biomarker studies. Principal investigator. National Institutes of Health. Sep 2015—Aug 2016. NIH R56 AG050650.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2016 Cincinnati Children's Hospital Medical Center. All rights reserved.